Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                The FDA Science Forum

The FDA Science Forum

                        The 2021 FDA Science Forum
          2023 FDA Science Forum Agenda Home
          Science & Research
          About Science & Research at FDA
          The FDA Science Forum
          2021 FDA Science Forum - 05/26/2021 - 05/27/2021The FDA Science Forum Forum
    Event Title
              2021 FDA Science Forum


                  May 26 - 27, 2021

  

    
  Share
    Post
    Linkedin

    Email
    PrintDate:
          
  


     
                                                       
       

May 26 - 27, 2021   

 
 
        
                
                          
                          Day1: 
                Wed, May 26
              
                          Day2: 
                Thu, May 27
                
  Organized By: 
      Organizer
          Office of the Chief Scientist

 







On this page:

Overview
	Sessions
	Recorded Webcasts
	Posters**The *2021 FDA Science Forum: Science as the Foundation for Protecting and Promoting Public Health* was held virtually on May 26-27, 2021.**

2021 FDA Science Forum Agenda

FDA's Science Forum offers an exciting opportunity for the public to view the unique scientific research and collaborative efforts of FDA’s 11,000 scientists. You'll get a chance to see first-hand how FDA's researchers are using novel science and technologies to inform FDA’s regulatory decision-making—and drive innovation.

FDA scientific experts and nationally renowned scientists will speak on the eight topics of the *2021 FDA Science Forum: Science as the Foundation for Protecting and Promoting Public Health*, highlighted below. This year’s keynote speaker is **NIAID Director Anthony Fauci, M.D.**

FDA’s Science Forum welcomes the public, industry, academia, patient advocates, sister agencies, and current and potential collaborators to join us virtually and learn about the critical contributions that FDA's regulatory science makes to product quality and safety.

Sessions

For more information, please see the 2021 FDA Science Forum Agenda.

**Day 1: Wednesday, May 26**

Keynote Session
	The session will include welcome remarks by the FDA Chief Scientist, RADM Denise Hinton, opening remarks and introduction of the keynote speaker by FDA Acting Commissioner, Dr. Janet Woodcock and the keynote address by Dr. Anthony Fauci.    
Session 1: Improving Clinical and Postmarket Evaluation
	This area of research notably exercises the use of real-world evidence (RWE), complex innovative trial design (CID), modeling informed product development, product safety surveillance and digital health. Data that comprise RWE include electronic health records, administrative claims, and patient-reported data via mobile devices. CID includes complex adaptive, Bayesian, and other trial designs that are used selectively to provide substantial evidence of effectiveness in new drug applications or biologics license applications. A common feature of many CIDs is the need for simulations rather than mathematical formulae to estimate trial operating characteristics. Model-informed drug development is an approach that involves developing and applying exposure-based, biological and statistical models derived from preclinical and clinical data sources to inform drug development and decision-making. Product safety surveillance includes the use of FAERS and VAERS. Digital health includes mobile health, health information technology, wearable devices, telehealth and telemedicine, and digital personalized medicine.    
Session 2: Tools to Effectively Use Big Data
	This theme highlights the use of artificial intelligence (AI) and big data. AI includes machine learning, deep learning, natural language processing, robotics, image recognition, etc. Big data are regularly amassed in nonclinical and clinical settings. The breadth, depth, and diversity of big data both benefits and supports knowledge gaps.    
Session 3: Empowering Patients and Consumers
	Social and behavioral science research promotes the development of clear communication methods to diverse consumer populations and patients; apprises researchers of patient/consumer preferences and perspectives; and disseminates new knowledge about methods used by patients and consumers to report their health status through different types of clinical outcome assessments, including patient-reported outcomes. A combination of strategies are applied to inform the regulatory review process, communication strategies, and policy development. These strategies include evidence-based approaches; evaluating the impact of communication and educational materials; and understanding consumer beliefs and attitudes.    
Session 4: Product Development and Manufacturing
	This area of research includes examining biomarkers, novel technologies (e.g., alternative methods for toxicity assessment), and advanced manufacturing. Advanced manufacturing is a collective term for medical product development and manufacturing that incorporates technology or established techniques using innovative methods with the potential to improve medical product quality, address product shortages, and speed time-to-market.

**Day 2: Thursday, May 27**

Session 5: Advancing Products Based on Novel Technologies
	Included in this area of study are regenerative medicine, individualized and precision medicine, and examination of the microbiome/microbiota. Regenerative medicine refers to a global approach to restore, replace, or regenerate cells, tissues, or organs to treat or mitigate disease or dysfunction (e.g., cell therapy). Individualized medicine refers to the development of therapeutics to address unmet medical needs respective of unique individual maladies. Precision medicine is an emerging approach for patient treatment decisions and disease prevention that considers genomic/genetic variabilities, environment, and lifestyle. The term microbiome/microbiota refers to the community of microbial organisms linked by physical location (ecosystems), function relationships, and collective genomic potential in homeostasis or dysbiosis. There is extensive data-based evidence that human, animal and environmental microbiota play significant and varied roles in states of health and disease.    
Session 6: Medical Countermeasures, Infectious Disease and Pathogen Reduction Technologies
	The focus of this research includes medical countermeasures and technologies to support pathogen reduction of FDA-regulated medical products. Medical countermeasures are FDA-regulated products (biologics, drugs, devices) that can be used to diagnose, prevent, protect from, or treat conditions caused by exposure to chemical, biological, radiological, nuclear threats, or emerging infectious diseases. This topic also includes the use of innovative technologies to reduce pathogen contamination and reduce or eliminate pathogens from FDA-regulated medical products to prevent transmission of infectious disease through their use.    
Session 7: Food and Cosmetic Safety
	Ensuring that the food people and animals eat is safe and protected from contamination is an essential element of promoting human and animal health. FDA ensures that the nation’s food and cosmetic supply is safe from harmful chemical, microbial (inclusive of antimicrobial resistance), and radiological contamination and other types of adulteration. FDA faces unique challenges in the oversight of human and animal food safety and cosmetic safety in the 21st century. The Agency oversees nearly 90% of the food supply for humans and animals, including domestically produced and imported products, as well as human dietary supplements and botanicals. This oversight and One Health approach includes continuous surveillance of the human and animal food supply for ongoing and emerging threats; development of methods for threat detection and quantitation; deployment of those methods to domestic and global partners; predictive toxicology and risk assessment; and strategic analysis of large amounts of data from numerous sources. Communication of these results and activities is vital to informing the public of the safety of the food supply both for them and their animals.    
Session 8: Substance Use, Misuse, and Addiction
	FDA regulates controlled substances and tobacco. The use or misuse of these products may lead to physical or psychological dependence. This topic will explore substance use and use disorders due to controlled substances, including prescription opioids, benzodiazepines, and stimulants. Substance misuse may include unintended use of products (i.e., for a different indication, through a different route of exposure) or intended use of a product that results in harm to users (e.g., tobacco). When evaluating regulated products, FDA considers product abuse liability and addiction potential. Some common measures important in determining the abuse liability of a product can include pharmacokinetics, patterns of use, and the subjective effects of that product.

Recorded Webcasts

2021 FDA Science Forum: Main Session and Keynote
	Session 1: Improving Clinical and Post-Market Evaluation
	Session 2: Tools to Effectively Use Big Data
	Session 3: Empowering Patients and Consumers
	Session 4: Product Development and Manufacturing
	Session 5: Advancing Products Based on Novel Technologies
	Session 6: Medical Countermeasures, Infectious Disease and Pathogen Reduction Technologies
	Session 7: Food and Cosmetic Safety
	Session 8: Substance Use, Misuse, and AddictionPosters
  Filters
        Keyword  
              Topic
         
          Clear Filters

  Title 
          Synopsis 
          Topic 
          Authors
          Contact
          Center

                                                                                  Content current as of:
      06/15/2021More Meetings,
      Conferences, and
      Workshops
        
        The FDA Science Forum

          
                        The 2021 FDA Science Forum
          2023 FDA Science Forum Agenda
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop